Company intelligence / Profile preview

广州雷恩康亚生物医药科技

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Rencom (Guangzhou) Biomedical Technology is a Chinese biotechnology company specializing in the development of mRNA-based therapeutics and vaccines. Founded in 2021 and based in Guangzhou, the company utilizes a proprietary lipid nanoparticle (LNP) delivery platform to create a pipeline targeting infectious diseases and oncology. Their lead research programs include mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). Rencom aims to provide innovative, high-quality mRNA solutions to address unmet medical needs through rapid-response technology. The company is an emerging player in the Guangdong-Hong Kong-Macao Greater Bay Area's life sciences sector.

Therapeutic areas: Infectious DiseasesOncology
Modalities: mRNA-based drugsLipid nanoparticle delivery therapyBiologicVaccine
Industry: Biotech

Beyond the preview

Go deeper on 广州雷恩康亚生物医药科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 广州雷恩康亚生物医药科技.

Explore the full profile